There is increasing evidence that cytokines may interact with each other to form a network, which can modulate the acute myelogenous leukemia (AML) cell growth. In vitro studies have demonstrated that both IL-4 and IL-10 can inhibit leukemia cell secretion of IL-1β, TNFo, and GM-CSF, whereas they increase the release of IL-1 ra. These observations suggest that IL-4 and IL-10 might inhibit the proliferation of leukemia cells in vitro by suppressing the production of IL-1 β, TNFα, and GM-CSF, and through upregulation of ILIra production. In this study, we have investigated the in vivo effects of IL-4 and IL-10 on cytokine production in AML patients. Serum IL-1 ra, IL-1 β, TNFα, GM-CSF, and SCF levels were measured in AML patients who received IL-4 or IL-10. Both IL-4 and IL-10 were found to increase serum IL-Ira levels. This finding is in accord with the in vitro studies. However, IL-4 increased serum GM-CSF levels, and IL-10 increased serum IL-1β and TNFα levels. These in vivo effects of the two cytokines differ from then- in vitro effects. Despite the similar effects of IL-4 and IL-10 on cytokine production by AML cells in vitro, different effects were observed in AML patients in vivo. IL-4 increased serum SCF levels, whereas IL-10 decreased serum SCF levels. IL-4 increased serum GM-CSF levels, while IL-10 had no effect on them. Although IL-10 increased serum IL-1β and TNFα levels, IL-4 had no effect on them. These findings indicate that the in vitro effects of IL-4 and IL10 do not necessarily reflect their in vivo effects, and that the complex effects of the two cytokines on serum cytokine levels make it difficult to predict their therapeutic potential.
|Original language||English (US)|
|Issue number||11 PART II|
|State||Published - Dec 1 2000|
ASJC Scopus subject areas
- Cell Biology